SEC Form 10-Q filed by Regeneron Pharmaceuticals Inc.
$REGN
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/24/2024 | $1175.00 → $1077.00 | Outperform → Market Perform | Leerink Partners |
| 3/12/2024 | $1125.00 | Outperform | Bernstein |
| 1/12/2024 | $884.00 → $1076.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 11/9/2023 | $800.00 | Hold | Deutsche Bank |
| 11/3/2023 | $950.00 | Mkt Perform → Outperform | Raymond James |
| 8/21/2023 | $720.00 → $992.00 | Hold → Buy | Canaccord Genuity |
| 8/21/2023 | $950.00 → $1050.00 | Perform | Oppenheimer |
| 6/28/2023 | $953.00 → $720.00 | Buy → Hold | Canaccord Genuity |
TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email deta
TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announces the following September 2024 investor events: Investor Conference Presentations • Morgan Stanley 22nd Annual Global Healthcare Conference at 11:30 a.m. ET on Wednesday, September 4, 2024 • 2024 Wells Fargo Healthcare Conference at 12:45 p.m. ET on Thursday, September 5, 2024 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days. Oncology Webcast Information • European Society for Medi
TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detail
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
On Thursday, Sanofi SA (NASDAQ:SNY) reported a second-quarter business operating income of 2.8 billion euros ($3.03 billion), up 3.2% year-over-year and 8.3% in constant currency. The company reported second-quarter sales of $11.57 billion (10.75 billion euros), beating the consensus of $11.37 billion. Sales increased 7.8% year over year and 10.2% on constant currency. Also Read: Europe Approves Sanofi/Regeneron’s Dupixent for ‘Smoker’s Lungs’ A Month After US FDA Asks For Data. The French drugmaker reported adjusted EPS of $0.93 (1.73 euros), beating the consensus estimate of $0.86, down 0.6% reported and up 4.0% at CER. Sales of Dupixent, Sanofi’s blockbuster eczema drug, rose
TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1030 to $1200.
On Tuesday, MAIA Biotechnology Inc (NASDAQ:MAIA) announced treatment updates from its Phase 2 THIO-101 trial of THIO sequenced with Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) cemiplimab (Libtayo) for advanced non-small-cell-lung-cancer patients who failed two or more standard-of-care therapy regimens. The trial’s therapeutic regimen is cycled every three weeks, with THIO 180mg administered in 60mg incremental doses on days 1, 2 and 3, followed by immune activation on day 4 (no dosing), and cemiplimab 350mg administered on day 5. As of the latest clinical cutoff date, June 12, 2024: Six patients remain on treatment following at least 12 months of therapy. Treatment with THIO f
S-3ASR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
10-Q - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one yearDupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial Paris and Tarrytown, NY, November 6, 2024. The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically,
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial TARRYTOWN, N.Y. and PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as 1 year of age. Specifically, the approval covers ch
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 years More than 300,000 people in the U.S. suffer from chronic spontaneous urticaria that is inadequately controlled by antihistamines TARRYTOWN, N.Y. and PARIS, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi will present positive data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent®
Leerink Partners downgraded Regeneron Pharma from Outperform to Market Perform and set a new price target of $1,077.00 from $1,175.00 previously
Bernstein initiated coverage of Regeneron Pharma with a rating of Outperform and set a new price target of $1,125.00
RBC Capital Mkts upgraded Regeneron Pharma from Sector Perform to Outperform and set a new price target of $1,076.00 from $884.00 previously
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis
TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie
NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for
TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company's Board of Directors and will not stand for reelection at the Company's 2023 Annual Meeting of Shareholders. Dr. Vagelos has served as Chair since January 1995 and will complete his current term through the conclusion of the Annual Meeting on June 9, 2023. Effective upon the conclusion of that meeting, the Board plans to appoint Leonard S. Schleifer, M.D., Ph.D., and George D. Yancopoulos, M.D., Ph.D., as Co-Chairs of the Board, in addition to their roles as President and Chief Executive Officer and P